Logo

Cisbio Inks Technology Licensing Deals, Collaborations for HTRF Technology

Aug 09, 2004

NEW YORK, Aug. 9 (GenomeWeb News) - Cisbio International said today that it has signed deals under which its homogenous time-resolved fluorescence technology will be incorporated into the measurement instrumentation systems used by BMG Labtech, Tecan, and Molecular Devices for drug discovery.

 

Under the terms of the agreements, each company will license Cisbio's HTRF technology for use in their high-performance time-resolved fluorescence microplate readers that are used in HTRF-based assays.

 

Cisbio also announced today that it has signed collaborations with Cell Signaling Technology and Upstate to expand use of the HTRF technology.

 

According to Cisbio, Cell Signaling has agreed to supply a select group of native antibodies and substrates that Cisbio will label and market for use in conjunction with HTRF. Separately, Upstate has agreed to use the HTRF technology with its assay for PI-3 kinase.

 

Additional terms of all five deals were not disclosed.

 

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.